Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)67.07
  • Today's Change0.13 / 0.19%
  • Shares traded1.05m
  • 1 Year change-21.56%
  • Beta0.2982
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,0741,2921,014
Total Receivables, Net634461373
Total Inventory1,107894777
Prepaid expenses------
Other current assets, total141105110
Total current assets2,9562,7512,274
Property, plant & equipment, net1,1121,1141,082
Goodwill, net196196196
Intangibles, net295339389
Long term investments622334508
Note receivable - long term------
Other long term assets114135105
Total assets6,8426,3756,003
LIABILITIES
Accounts payable------
Accrued expenses323318277
Notes payable/short-term debt000
Current portion long-term debt/capital leases4942.292.27
Other current liabilities, total453867
Total current liabilities1,177589540
Total long term debt5931,0831,081
Total debt1,0871,0851,083
Deferred income tax------
Minority interest------
Other liabilities, total120100112
Total liabilities1,8901,7721,733
SHAREHOLDERS EQUITY
Common stock0.190.190.18
Additional paid-in capital5,6125,4055,192
Retained earnings (accumulated deficit)(622)(789)(926)
Treasury stock - common------
Unrealized gain (loss)0.87(12)(1.37)
Other equity, total(40)(0.63)6.12
Total equity4,9524,6034,271
Total liabilities & shareholders' equity6,8426,3756,003
Total common shares outstanding189186184
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.